Welcome to the e-CCO Library!

OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Sazonovs1*, N.A. Kennedy2, C. Bewshea2, L. Moutsianas1, G.J. Walker2, K. De Lange1, J. Goodhand2, C. Anderson1, J. Barrett1, PANTS Investigator Consortium, T. Ahmad2

Created: Thursday, 21 February 2019, 9:14 AM
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Sazonovs Aleksejs
Created: Friday, 23 March 2018, 12:23 PM
Last Modified: Thursday, 5 July 2018, 10:50 AM by Lindley Fritze
OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohns disease refractory to anti-tumour necrosis factor α: UNITI-1
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Rutgeerts*1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B. Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9, J.-F. Colombel10, S. Lee11, P. Desreumaux12, E. V. Loftus, Jr13, S. Vermeire14, W. J. Sandborn15

Created: Friday, 22 February 2019, 9:49 AM
OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome
Year: 2018
Source: ECCO'18 Vienna
Authors: Vich Vila Arnau
Created: Friday, 23 March 2018, 12:23 PM
Last Modified: Thursday, 5 July 2018, 10:51 AM by Lindley Fritze
Files: 1
OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for inflammatory bowel disease and irritable bowel syndrome
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Vich Vila1*, F. Imhann1, V. Collij1, S.A. Jankipersadsing1, T. Gurry2, Z. Mujagic3, A. Kurilshikov1, M.J. Bonder1, J. Xiaofang2, E. Tigchelaar1, J. Dekens1, V. Peters1, M.D. Voskuil1, M.C. Visschedijk1, F. Eleonora A.M.1, G. Dijkstra1, A.A. Masclee3, M.H. Hofker1, R. Xavier4, E.J. Alm2, J. Fu1, C. Wijmenga1, D.M. Jonkers3, A. Zhernakova1, R.K. Weersma1

Created: Thursday, 21 February 2019, 9:14 AM
OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Last Modified: Wednesday, 15 March 2017, 2:49 PM by ECCO Administrator
Ozanimod, Histological remission
Files: 1
OP014: Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.1, Feagan B.*2, D'Haens G.3, Levesque B.2, Pai R.4, Hanauer S.5, Wolf D.6, Vermeire S.7, Ghosh S.8, Li C.9, Penenberg D.9, Aranda R.9, Olson A.9

Created: Wednesday, 20 February 2019, 10:36 AM
OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Reinisch1*, R. Panaccione2, P. Bossuyt3, F. Baert4, A. Armuzzi5, S. Travis6, S. Danese7, W.J. Sandborn8, G. D'Haens9, S. Berg10, J.-F. Maa11, J. Petersson11, E. Neimark11, A.M. Robinson11, J.-F. Colombel12

Created: Thursday, 21 February 2019, 9:14 AM
OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn’s Disease: Data from CALM
Year: 2018
Source: ECCO'18 Vienna
Authors: Reinisch Walter
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C TRIAL
Year: 2017
Source: ECCO '17 Barcelona
Authors:

de Groof J.*1,2, Bemelman W.1, Eshuis E.2, Gardenbroek T.1, Bossuyt P.3, Bosmans J.4, van Dongen H.4, van Wagensveld B.5, Brink M.6, Consten E.7, Buskens C.1, D'Haens G.2, Stokkers P.8, Ponsioen C.2 LIR!C Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIR!C TRIAL
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Groof J.
Last Modified: Wednesday, 15 March 2017, 2:47 PM by ECCO Administrator
Crohn's disease, Ileo caecal resection, Laparoscopic surgery, Infliximab
Files: 1
OP015: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohns disease who are anti-tumour necrosis factor inadequate responders
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Danese*1, S. Vermeire2, P. Hellstern3, R. Panaccione4, G. Rogler5, G. Fraser6, A. Kohn7, P. Desreumaux8, R.W. Leong9, G.M. Comer10, F. Cataldi10, A. Banerjee10, M.K. Maguire11, C. Li10, N. Rath11, J. Beebe10, S. Schreiber12

Created: Friday, 22 February 2019, 9:49 AM
OP016: Development and validation of diagnostic criteria for IBD-unclassified (IBDU) in children: a multicentre longitudinal study from the paediatric IBD Porto Group of ESPGHAN
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Birimberg Schwartz1, D. Zucker2, A. Akriv2, C. Salvatore3, F. Cameron4, I. Lazowska5, L. Yianni6, P. Siba7, S. Kolacek8, C. Romano9, S. Buderus10, A. Pærregaard11, J. C. Escher12, D. Turner*13

Created: Friday, 22 February 2019, 9:49 AM
OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased: a nationwide study of temporal trends in Crohn surgery in Sweden 1990–2014
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Kalman1*, C. Nordenvall2, A. Hallqvist Everhov3, J.F. Ludvigsson4, M.C. Sachs5, A. Ekbom6, O. Olén7, P. Myrelid1

Created: Thursday, 21 February 2019, 9:14 AM
OP016: Potential role of bile acid receptor FXR in microscopic colitis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Palmela C.
Last Modified: Wednesday, 15 March 2017, 2:17 PM by Vesna Babaja
Histology, Microscopic colitis
Files: 1
OP016: Potential role of bile acid receptor FXR in microscopic colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Palmela C.*1, Torres J.1, Gomes de Sena P.2, Costa Santos M.P.1, Gouveia C.1, Oliveira M.H.2, Rodrigues C.M.P.3, Cravo M.1, Borralho P.4,5

Created: Wednesday, 20 February 2019, 10:36 AM
OP017: Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Paramsothy*1, M. Kamm2, 3, A. Walsh4, J. van den Bogaerde5, D. Samuel6, R. Leong6, S. Connor7, W. Ng7, R. Paramsothy7, N. Kaakoush8, H. Mitchell8, W. Xuan9, E. Lin10, T. Borody10

Created: Friday, 22 February 2019, 9:49 AM
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Jong M.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by Vesna Babaja
Disease activity Indices, Patient reported outcomes, Quality of life, IBD nurse
Files: 1
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoach
Year: 2017
Source: ECCO '17 Barcelona
Authors:

de Jong M.*1,2, van der Meulen-de Jong A.3, Romberg-Camps M.4, Becx M.5, Cilissen M.1, Maljaars J.3, van Bodegraven A.4, Mahmmod N.5, Markus T.6, Hameeteman W.1, Dijkstra G.7, Masclee A.1,2, Boonen A.8,9, Jonkers D.1,2, van Tubergen A.8,9, Pierik M.1,2

Created: Wednesday, 20 February 2019, 10:36 AM